FindlingRL, RobbA, NyilasM, ForbesRA, JinN, IvanovaS, MarcusR, McQuadeRD, IwamotoT, CarsonWH. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry, 165:1432–1441. 2008a.
5.
FindlingRL, ShortEJ, LeskovecT, TownsendLD, DemeterCA, McnamaraCK, StansbreyRJ. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 18:347–354. 2008b.
HollisC. Adult outcomes of child- and adolescent-onset schizophrenia: Diagnostic stability and predictive validity. Am J Psychiatry, 157:1652–1659. 2000.
8.
KaraguzelG, AckurinS, YakutS, BircanI. Reported on a case of 22q11 deletion syndrome, associated with psychiatric disorder, precocious puberty and hypoparathyroidism. J Pediatr Endocrinol Metabolism, 19:761–764. 2006.
9.
KernRF, GreenMF, CornblattBA, OwenJR, McQuadeRD, CarsonWH, AliM, MarcusR. The neurocognitive effect of aripiprazole: An open label comparison with olanzapine. Psychopharmacology, 187:312–320. 2006.
KumraS, OberstarJV, SikichL, FindlingRL, McClellanJM, VinogradovS, Charles SchulzS. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophrenia Bull, 34:60–71. 2008a.
12.
KumraS, KranzlerH, Gerbino-RosenG, KesterHM, DeThomasC, KafantarisV, CorrellCU, KaneJM. Clozapine and “high dose” olanzapine in refractory early-onset schizophrenia: A 12 week randomized and double-blind comparison. Biol Psychiatry, 63:524–529. 2008b.
13.
MasiG, MucciM, PariC. Children with schizophrenia: Clinical picture and pharmacological treatment. CNS Drugs, 20:841–866. 2006.
PopeHG, ColeJO, ChorasPT, FulwilerCE. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis, 174:493–495. 1986.
16.
PrasadSE, HowleyS, MurphyKC. Psychiatric disorders in people with 22q11.2 deletion syndrome: A population-based prevalence study in Ireland. J Intellect Disabil Res, 52:816. 2008.
ShinL, BregmanH, FrazierJ, NovesN. An overview of obesity in children with psychiatric disorders taking atypical antipsychotics. Harv Rev Psychiatry, 16:69–79. 2008.
TyEB, RothnerAD. Neuroleptic malignant syndrome in children and adolescents. J Child Neurol, 16:157–163. 2001.
21.
WerryJS, McClellanJM. Predicting outcome in child and adolescent (early onset) schizophrenia and bipolar disorder. J Am Acad Child Adolesc Psychiatry, 31:147–150. 1992.
22.
YildizA, GuleryuzS, AnkerstDP, OngurD, RenshawPF. Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry, 65:255–263. 2008.
23.
ZarateCAJr, SinghJB, CarlsonPJ, QuirozJ, JolkowskyL, LuckenbaughDA, ManjiHK. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord, 9:561–570. 2007.